000			nab a22 7a 4500
999			_c17349 _d17349
003			PC17349
005			20230329133955.0
008			230329b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9891 _aVanaclocha Sebastián, Francisco _eDermatología Médico Quirúrgica y Venereología
245	0	0	_aSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. _h[artículo]
260			_bJournal of the American Academy of Dermatology, _c2015
300			_a73(3):400-9.
500			_aFormato Vancouver: Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400-9.
501			_aPMID: 26092291
504			_aContiene 28 referencias
520			_aBackground: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). Objective: We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. Methods: In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 to subcutaneous injection of secukinumab 300 mg or ustekinumab per label. Primary end point was 90% or more improvement from baseline Psoriasis Area and Severity Index (PASI) score (PASI 90) at week 16. Results: Secukinumab (79.0%) was superior to ustekinumab (57.6%) as assessed by PASI 90 response at week 16 (P < .0001). The 100% improvement from baseline PASI score at week 16 was also significantly greater with secukinumab (44.3%) than ustekinumab (28.4%) (P < .0001). The 75% or more improvement from baseline PASI score at week 4 was superior for secukinumab (50.0%) versus ustekinumab (20.6%) (P < .0001). Percentage of subjects with the Dermatology Life Quality Index score 0/1 (week 16) was significantly higher with secukinumab (71.9%) than ustekinumab (57.4%) (P < .0001). The safety profile of secukinumab was comparable with ustekinumab and consistent with pivotal phase III secukinumab studies. Limitations: The study was not placebo-controlled and of short-term duration. Conclusions: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe psoriasis and improving health-related quality of life with a comparable safety profile over 16 weeks.
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17349.pdf _ySolicitar documento
942			_2ddc _cART _n0